Virtus ETF Advisers LLC Nkarta, Inc. Transaction History

Virtus ETF Advisers LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$3.37 - $6.3 $17,908 - $33,478	-5,314 Reduced 27.77%	13,821 $49,000
Q4 2022 Feb 14, 2023	BUY	$5.14 - $14.35 $54,273 - $151,521	10,559 Added 123.12%	19,135 $114,000
Q3 2022 Nov 14, 2022	BUY	$12.27 - $18.39 $760 - $1,140	62 Added 0.73%	8,576 $113,000
Q2 2022 Aug 12, 2022	SELL	$7.77 - $19.44 $28,065 - $70,217	-3,612 Reduced 29.79%	8,514 $105,000
Q1 2022 May 16, 2022	SELL	$8.66 - $14.99 $6,209 - $10,747	-717 Reduced 5.58%	12,126 $138,000
Q4 2021 Feb 14, 2022	BUY	$12.79 - $26.88 $62,952 - $132,303	4,922 Added 62.14%	12,843 $197,000
Q3 2021 Nov 15, 2021	SELL	$26.67 - $38.76 $11,094 - $16,124	-416 Reduced 4.99%	7,921 $220,000
Q2 2021 Aug 10, 2021	BUY	$23.94 - $36.68 $96,382 - $147,673	4,026 Added 93.39%	8,337 $264,000
Q1 2021 May 17, 2021	BUY	$31.33 - $59.61 $2,255 - $4,291	72 Added 1.7%	4,311 $142,000
Q4 2020 Feb 12, 2021	BUY	$27.03 - $75.62 $114,580 - $320,553	4,239 New	4,239 $261,000

129

66.5M

173K

20K

Ticker NKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,656,800
Market Cap $127M
Description
Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the sur...

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

Stay updated on Virtus ETF Advisers LLC with notifications on news.